Selexipag for the treatment of pulmonary arterial hypertension. (4th May 2021)

• Record Type: Journal Article
• Authors: Genecand, Léon; Wacker, Julie; Beghetti, Maurice; Lador, Frédéric
• Is Part Of: Expert review of respiratory medicine. Volume 15:Number 5(2021)
• Page Start: 583
• Page End: 595
• Publication Date: 2021-05-04
• Subjects: Endothelin receptor antagonist -- guanylate cyclase stimulators -- phosphodiesterase type 5 inhibitor -- pulmonary arterial hypertension -- prostacyclin Pathway -- selexipag; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2021.1866990
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Introduction: : Pulmonary arterial hypertension (PAH) is a rare pulmonary vasculopathy. This review focuses on selexipag, a prostacyclin receptor agonist validated for the treatment of PAH. Areas covered: We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis. Expert opinion: Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.